Hologic faces a challenging post-pandemic transition characterized by muted 2.5% year-over-year revenue growth in 2026Q1 and significant earnings volatility. While the company maintains a healthy balance sheet with a 0.48 debt-to-equity ratio, its reliance on ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remains constrained at 2.5% in 2026Q1, while gross margins have fluctuated significantly from a low of 37.5% in 2025Q2 to 56.0% in the most recent quarter.
Hologic specializes in diagnostics, surgical, and medical imaging technologies dedicated to advancing women's health, a growing and underserved market.
The company has received all necessary regulatory approvals for its $18.3 billion sale to private equity firms, signaling strong investor confidence.
With a current stock price around $65.16, Hologic may present a buying opportunity for growth investors in the healthcare equipment sector.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q1 2026Latest Jan 29, 2026 | $1.04-4.6% vs $1.09 | $1.0B-2.2% vs $1.1B |
Q4 2025 Nov 3, 2025 | $1.13+2.7% vs $1.10 | $1.0B+1.5% vs $1.0B |
Q3 2025 Jul 30, 2025 | $1.08+2.9% vs $1.05 | $1.0B+1.3% vs $1.0B |
Q2 2025 May 1, 2025 | $1.03+1.0% vs $1.02 | $1.0B+0.5% vs $1.0B |
Private equity groups Blackstone and TPG are seeking more than $4 billion for medical technology firm Hologic's surgical unit, the Financial Times reported on Thursday, citing people familiar with the matter.
Benchmark HOLX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Hologic, Inc. (HOLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $76.01 | $16.97B | 30.53 | 1.74% | 13.8% | 11.12% | — | |
| $183.00 | $50.42B | 31.39 | 8.23% | 4.52% | 3.79% | — | |
| $23.68 | $12.23B | -13.53 | 5.72% | -9.27% | -16.67% | — | |
| $521.50 | $41.14B | 39.87 | 10.42% | 25.03% | 71.96% | — | |
| $89.53 | $34.55B | 42.84 | 15.6% | 20.12% | 36.19% | — | |
| $402.09 | $142.05B | 51.09 | 20.51% | 28.45% | 17.71% | — |
Hologic, Inc. (HOLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Hologic, Inc. (HOLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 7, 2026·SEC
Apr 6, 2026·SEC
Feb 6, 2026·SEC
Get notified when HOLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Hologic, Inc. (HOLX) stock FAQ — growth, dividends, profitability & financials explained
Hologic, Inc. (HOLX) reported $4.13B in revenue for fiscal year 2025. This represents a 4578% increase from $88.2M in 1996.
Hologic, Inc. (HOLX) grew revenue by 1.7% over the past year. Growth has been modest.
Yes, Hologic, Inc. (HOLX) is profitable, generating $543.9M in net income for fiscal year 2025 (13.8% net margin).
Hologic, Inc. (HOLX) has a return on equity (ROE) of 11.1%. This is reasonable for most industries.
Hologic, Inc. (HOLX) generated $999.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
